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Pancreatic ductal adenocarcinoma (PDA) remains one of the most
lethal tumor types, with extremely low survival rates due to late
diagnosis and resistance to standard therapies. A more compre-
hensive understanding of the complexity of PDA pathobiology,
and especially of the role of the tumor microenvironment in
disease progression, should pave the way for therapies to improve
patient response rates. In this study, we identify galectin-1 (Gal1),
a glycan-binding protein that is highly overexpressed in PDA
stroma, as a major driver of pancreatic cancer progression. Genetic
deletion of Gal1 in a Kras-driven mouse model of PDA (Ela-
KrasG12Vp53−/−) results in a significant increase in survival through
mechanisms involving decreased stroma activation, attenuated
vascularization, and enhanced T cell infiltration leading to dimin-
ished metastasis rates. In a human setting, human pancreatic stel-
late cells (HPSCs) promote cancer proliferation, migration, and
invasion via Gal1-driven pathways. Moreover, in vivo orthotopic
coinjection of pancreatic tumor cells with Gal1-depleted HPSCs
leads to impaired tumor formation and metastasis in mice. Gene-
expression analyses of pancreatic tumor cells exposed to Gal1 reveal
modulation of multiple regulatory pathways involved in tumor pro-
gression. Thus, Gal1 hierarchically regulates different events impli-
cated in PDA biology including tumor cell proliferation, invasion,
angiogenesis, inflammation, and metastasis, highlighting the broad
therapeutic potential of Gal1-specific inhibitors, either alone or in
combination with other therapeutic modalities.
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Of all solid tumors, pancreatic ductal adenocarcinoma (PDA)has the direst prognosis; in the absence of any significant
advance in its treatment or early diagnosis, it is projected to be-
come the second leading cause of cancer death in the United
States by 2030 (1). In addition to late diagnosis, a major factor for
this dismal prognosis is the high resistance of PDA to therapies,
which has been associated to its hostile tumor microenvironment
(2, 3). PDA represents a paradigm of oncogenic tumor–stroma
crosstalk, as stromal components represent up to 90% of the
pancreatic tumor volume and are co-opted by tumor cells to favor
tumor progression. Accordingly, targeting PDA stroma has re-
cently emerged as a promising strategy to fight against this fatal
disease (4–8). Numerous studies, however, have unveiled the
complexity and delicate balance between the detrimental and
beneficial effects of tumor–stroma interactions in PDA (9–12).
The pancreatic tumor microenvironment contains abundant
extracellular matrix proteins, endothelial cells, immune cells, and
cancer-associated fibroblasts (CAFs). Activated pancreatic stel-
late cells (PSCs) represent most of the CAFs in pancreatic tu-
mors and are characterized by α-smooth muscle actin (α-SMA)
expression and the secretion of numerous factors favoring tumor
progression (13–19). Besides the abundant presence of CAFs,
the PDA stroma is also characterized by a highly immunosup-
pressive microenvironment, with increased numbers of regula-
tory cells, such as myeloid-derived suppressor cells (MDSCs),
M2-type macrophages, and Foxp3+ regulatory T lymphocytes
(Tregs), together with a conspicuous absence of effector (CD4+
and CD8+) T cells. This scenario leads to profound immune
evasion that might explain, at least in part, why pancreatic cancer
is fully refractory to immunotherapeutic modalities (20–23).
Increasing knowledge has led to the identification of the mo-
lecular alterations responsible for PDA tumor initiation and
progression. Mutations in KRAS, which are found in more than
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90% of human PDAs, occur in the earliest steps of tumor
progression (24), followed by alterations in tumor-suppressor
genes, including TP53, SMAD4, and CDKN2A (25). Geneti-
cally engineered mouse models (GEMMs) are essential tools for
studying the molecular mechanisms underlying PDA progression
and for evaluating potential therapeutic targets (26). In particular,
GEMMs harboring pancreas-specific mutated KRAS are cur-
rently considered the best models to mirror human pathology, as
these mice develop the full spectrum of pancreatic tumor pro-
gression, from metaplastic and preneoplastic lesions to adenocar-
cinoma and metastasis (27–32). Moreover, tumors from Kras-driven
mouse models of PDA present high histopathological similarities to
human PDA, including abundant desmoplastic stroma (26) and a
prominent immunosuppressive microenvironment (33).
Galectins are a family of glycan-binding proteins composed of
15 members with shared structural homology (34–36). Galectin-1
(Gal1), a prototype member of this family, plays major roles in
cancer by modulating different processes leading to tumor pro-
gression (34–38). Several reports have shown increased Gal1
expression in human cancer, including PDA (39–42). Using a
c-myc–driven murine PDA model, we demonstrated that this
lectin exerts a broad range of protumoral effects (43). In-
terestingly, Gal1 expression in pancreatic tumors is expressed
mostly within the stromal compartment (39, 41–43), displaying in
vitro and in vivo protumoral effects (18, 44–47). However, the
precise role and molecular mechanisms responsible for Gal1-
mediated tumor–stroma crosstalk and their translation into the
complex pathobiology of PDA are puzzling and not fully un-
derstood. We therefore sought to determine the role of Gal1 in
PDA tumor progression by analyzing the biological conse-
quences of its genetic deletion in a Kras-driven mouse model of
pancreatic cancer (Ela-KrasG12Vp53−/−). Further, using patient-
derived PSCs and pancreatic cancer cells, we modeled the human
PDA tumor–stroma crosstalk. These data demonstrate in vitro
and in vivo that Gal1 plays a critical role in PDA progression.
Results
Gal1 Deletion Increases Survival in the Ela-KrasG12Vp53−/− Model of
Pancreatic Cancer. The Kras+/LSLG12Vgeo; p53lox/lox;Elas-tTA;TetO-
Cre (herein “Ela-KrasG12Vp53−/−”) transgenic model, which ex-
presses the KrasG12V oncogene in pancreatic acinar cells using an
elastase-driven inducible Tet-Off strategy (48), is considered one
of the best models for studying PDA in the preclinical setting, as
it faithfully recapitulates the natural history and hallmarks of this
disease (28, 48). Ela-KrasG12Vp53−/− mice develop ductal tumors
displaying abundant desmoplasia with extensive extracellular
matrix protein deposition and activated α-SMA+ positive PSCs
(Fig. 1A). Immunohistochemical analysis for Gal1 showed high
expression in the stromal compartment (Fig. 1A), recapitulating
the pattern found in human PDA (39, 43). To determine the role
of Gal1 in pancreatic tumor formation and progression, we crossed
Ela-KrasG12Vp53−/−mice with mice lacking the Gal1 gene (Lgals1−/−).
After generation of the Ela-KrasG12Vp53−/−Lgals1+/+, Ela-KrasG12V
p53−/−Lgals1+/−, and Ela-KrasG12Vp53−/−Lgals1−/− mice, we selected
the Ela-KrasG12Vp53−/−Lgals1+/+ and Ela-KrasG12Vp53−/−Lgals1−/−
genotypes for further characterization, as Gal1 heterozygotes showed
no phenotypic differences from Lgals1+/+ mice. Ela-KrasG12Vp53−/−
Lgals1−/− mice developed ductal pancreatic tumors with histopath-
ological hallmarks similar to those in tumors from Ela-KrasG12Vp53−/
−Lgals1+/+ mice (Fig. 1A). However, we observed a significant in-
crease (22.3%) in the lifespan of Gal1-KO (Lgals1−/−) mice (Fig. 1B).
Interestingly, these differences became more evident when short-
term and long-term survivors were compared. Specifically, 10% of
Ela-KrasG12Vp53−/−Lgals1+/+ mice died before 3 mo, and only 20%
survived more than 6 mo. In the absence of Gal1, survival changed to
5.3% for short-term survivors (a 47% decrease) and 36.8% for long-
term survivors (an 84% increase) (Fig. 1C and Table S1).
Gal1 Deletion Delays Tumorigenesis and Impairs Tumor Progression in
Ela-KrasG12Vp53−/− Mice. To define whether the survival phenotype
observed was a consequence of delayed tumor onset and/or pro-
gression, 4-mo-old mice were killed, and tumors were analyzed.
Histological characterization of pancreata showed that both Ela-
KrasG12Vp53−/−Lgals1+/+ and Lgals1−/− mice displayed the full
spectrum of PDA progression at 4 mo, including normal pancreas,
acinar-to-ductal metaplasia and precursor lesions, and fully de-
veloped ductal pancreatic tumors with one or multiple nodules
(Fig. 2A). Interestingly, Lgals1−/− animals showed a less aggressive
lesion distribution, characterized by an increased number of nor-
mal pancreata, precursor lesions, and uninodular tumors com-
pared with Lgals1+/+ mice (Fig. 2B). Quantitative analysis showed
a significant decrease in the number of nodules per animal in the
Ela-KrasG12Vp53−/−Lgals1−/− compared with Lgals1+/+ mice (Fig.
2C). These data suggest that Gal1 expression in tumor stroma may
favor PDA initiation and tumor foci development.
Next, we explored the effects of Gal1 genetic ablation on PDA
tumor progression by analyzing metastasis formation. One of the
interesting features of the Ela-KrasG12Vp53−/− model is the
generation of tumor metastases located in the liver and lung,
which recapitulate those observed in the human condition. In-
terestingly, the presence of liver metastases was significantly and
selectively reduced in mice harboring Lgals1−/− tumors com-
pared with Lgals1+/+ mice (Fig. 2D). These data support a role
for Gal1 in PDA initiation, progression, and metastasis.
Gal1 Deletion Reduces Stroma Activation, Decreases Angiogenesis,
and Enhances Immune Cell Recruitment in Ela-KrasG12Vp53−/− Mice.
Due to the high levels of Gal1 expression in the PDA stroma
and the previously reported role of this lectin in the regulation of
immune and endothelial cell function (43), we sought to examine
the impact of Gal1 inactivation in the tumor microenvironment.
Characterization of the primary tumors developed at 4 mo by
Ela-KrasG12Vp53−/−Lgals1+/+ or Ela-KrasG12Vp53−/−Lgals1−/−
mice revealed that Gal1-deficient mice showed significantly
smaller tumors than Lgals1+/+ mice (Fig. 3A). Immunohisto-
chemical analysis showed that the decreases in tumor weight
were not associated with impaired proliferation or increased
tumor apoptosis or necrosis (Fig. S1A). However, Ela-KrasG12V
p53−/− tumors that developed in the absence of Gal1 showed
impaired stroma activation and decreased tumor vascularization
Fig. 1. Gal1 deficiency increases lifespan in the Ela-KrasG12Vp53−/− PDA mouse
model. (A) H&E staining and Gal1, CK19, and α-SMA IHC in tumor samples from
Ela-KrasG12Vp53−/−Lgals1+/+ and Ela-KrasG12Vp53−/−Lgals1−/− mice. (Scale bars:
100 μm for H&E, Gal1, and α-SMA staining and 50 μm for CK19.) (B) Kaplan–
Meier survival curves for Ela-KrasG12Vp53−/−Lgals1+/+ (n = 20) and Ela-
KrasG12Vp53−/−Lgals1−/− (n = 19) mice. *P < 0.05, log-rank test. (C) Pie charts
showing a summary of survival data indicating animals that survived less than
3 mo (short-term), 3–6 mo, or >6 mo (long-term). *P < 0.05, χ2 test.
E3770 | www.pnas.org/cgi/doi/10.1073/pnas.1722434115 Orozco et al.
(Fig. 3B and Fig. S1B), which could, at least in part, contribute to
the reduction of tumor size.
Given the well-established role of Gal1 in immune evasion (35,
49), we also considered the possibility that decreased tumor size
after Gal1 deletion could be associated with altered frequency of
effector versus regulatory immune cells. We thus analyzed tumor-
associated immune cell infiltrates from Ela-KrasG12Vp53−/−
Lgals1+/+ or Lgals1−/− tumors by flow cytometry. Tumor infiltrates
from Ela-KrasG12Vp53−/−Lgals1+/+ mice showed a paucity of in-
filtrating T cells and a high proportion of myeloid cell populations
(Fig. 3C). In contrast, Ela-KrasG12Vp53−/−Lgals1−/− tumors were
accompanied by an increased frequency of T lymphocytes (CD45+
CD3+) (Fig. 3C). Detailed analysis of T-cell subsets revealed that
the numbers of CD4+ T cells and CD8+ cytotoxic T cells were
enriched in Gal1-KO tumors compared with Ela-KrasG12Vp53−/−
Lgals1+/+ tumors (Fig. 3C). These data were confirmed by im-
munohistochemical analysis of immune cell infiltrates (Fig. S2A).
Of note, Tregs were rarely found in either Lgals1+/+ or Lgals1−/−
tumors, as shown by Foxp3 staining (Fig. S2B). Finally, changes in
immune cell infiltrates were not restricted to only the lymphoid
lineage, as the proportion of CD11b+Gr1+ MDSCs was strongly
reduced in Ela-KrasG12Vp53−/−Lgals1−/− tumors (Fig. 3C). Thus,
Gal1 could effectively promote an immunosuppressive microenvi-
ronment impairing lymphocyte infiltration and facilitating MDSCs
expansion.
Together, these results point to a key role for Gal1 in PDA
tumorigenesis and progression in the Ela-KrasG12Vp53−/− mouse
model via the induction of an activated stroma, increased angio-
genesis, and inhibition of immune cell infiltration. Thus, targeting
the Gal1–glycan axis may offer new therapeutic opportunities for
PDA patients.
Human PSCs Drive in Vitro Pancreatic Tumor Migration, Invasion, and
Proliferation via Gal1. To explore whether our findings using the
Kras-driven PDA mouse model could be translated to human
pathology and to gain further insights into the molecular mecha-
nisms underlying Gal1 functions in pancreatic cancer, we designed
a human cell-based experimental system to mirror tumor–stroma
crosstalk. For this, we used immortalized PSCs isolated from hu-
man PDA samples (human pancreatic stellate cells; HPSCs) (14)
that express high endogenous levels of Gal1 (43) and two human
pancreatic tumor cell lines (RWP-1 and BxPC-3) with undetect-
able/low levels of Gal1 expression (42). Gal1 knockdown in
HPSCs (Fig. S3 A and B) resulted in impaired cell activation,
shown by reduced levels of fibroblast activation markers (Fig. S3 C
and D), morphological changes (Fig. S3E), and decreased migra-
tion and invasion (Fig. S3 G and H), while not affecting cell
proliferation (Fig. S3F). To investigate the paracrine effects of
PSC-secreted Gal1 in PDA epithelial cells, we used conditioned
medium from control or Gal1-knocked down (shGal1) HPSCs
(Fig. 4 A and B) to treat RWP-1 cells. Remarkably, conditioned
medium from control HPSCs (either untransfected or transfected
with an irrelevant shRNA) induced proliferation, migration, and
invasion in RWP-1 cells (Fig. 4 C–E), while these effects were
significantly impaired when Gal1-depleted (shGal1) HPSC su-
pernatant was used. Similar results were obtained using the BxPC-
3 pancreatic tumor cell line (Fig. S4). Thus, HPSCs accentuate the
tumorigenic capacity of pancreatic epithelial cells via paracrine
secretion of Gal1.
Human PSCs Drive in Vivo Pancreatic Tumor Progression via Gal1. To
further investigate the role of HPSC-derived Gal1 in pancreatic
tumor–stroma crosstalk during in vivo cancer progression, we used
a xenograft orthotopic model of PDA in which HPSCs, either
stably depleted of Gal1 (shGal1) or transfected with a scrambled
shRNA (shSC) sequence, and BxPC-3 pancreatic tumor cells were
coinjected in a 5:1 ratio to mirror the high fibrotic component of
human tumors. Xenografts from BxPC-3 cells alone were used as a
negative control, and two different Gal1-specific shRNA se-
quences were used to rule out off-target effects (Fig. 5). As pre-
viously reported (14), we found that the stroma worked
synergistically with pancreatic tumor cells to accelerate tumor
progression. Specifically, tumors generated after coinjection of
BxPC-3 cells with control HPSCs were larger than those injected
with BxPC-3 cells alone (Fig. 5A). Remarkably, Gal1 depletion
in the coinjected HPSCs significantly reduced tumor size to a mag-
nitude similar to that of tumors generated with BxPC-3 cells alone
(Fig. 5A). Histopathological analysis of the pancreatic tumors
revealed large undifferentiated ductal tumors with central necrotic
cores (Fig. 5B). Detailed immunohistochemical analysis showed no
significant differences in tumor proliferation or angiogenesis (Fig.
5C). However, in line with results obtained in the Kras-driven
mouse PDA model, tumors generated after coinjection of BxPC-
3 cells with Gal1-depleted HPSCs exhibited a significant decrease
in the amount of active stroma (Fig. 5C). Moreover, we also ob-
served increased metastasis formation in mice coinjected with
BxPC-3 cells and control HPSCs as compared with mice inocu-
lated with BxPC-3 cells alone or coinjected with BxPC-3 tumor
cells mixed with Gal1-depleted HPSCs (Fig. 5D). These findings
support a role for HPSC-secreted Gal1 as one of the key mediators
of the interplay between the stroma and the epithelium to promote
in vivo tumor growth and progression in human PDA.
Fig. 2. Analysis of pancreatic lesions from 4-mo-old Ela-KrasG12Vp53−/−Lgals1+/+ or Ela-KrasG12Vp53−/−Lgals1−/− mice. (A) H&E-staining characterization of normal
pancreas (a and d) and preneoplastic (e) and tumor (b, c, and f) lesions found in 4-mo-old Ela-KrasG12Vp53−/−Lgals1+/+ and Ela-KrasG12Vp53−/−Lgals1−/− mice. (Scale
bars: 50 μm in a and d, 20 μm in b, and 100 μm in c, e, and f.) (B) Bar chart showing the percentage of mice with different types of lesions at 4 mo, when Ela-
KrasG12Vp53−/−Lgals1+/+ (n = 17) and Ela-KrasG12Vp53−/−Lgals1−/− (n = 18) mice were killed. Animals were classified according to the highest histological grade
lesion observed. (C) Representative images (Upper) and number of nodules in each tumor (Lower). (Scale bars: 1 mm.) *P < 0.05. (D, Upper) Liver and lung pancreatic
metastases stained with anti-CK19 antibody. (Lower) Quantification showing the percentage of mice with metastases. (Scale bars: 50 μm.) *P < 0.05 (χ2 test).

















Molecular Pathways Activated by Gal1 on Pancreatic Epithelial Cells. To
understand the molecular mechanisms underlying the paracrine
effects exerted by stromal Gal1 on the pancreatic epithelial
compartment, we performed a high-throughput analysis using
microarrays. To specifically address Gal1-driven pathways, we
avoided using conditioned medium from HPSCs (which may
contain several secreted factors) and instead treated RWP-1 pan-
creatic tumoral cells with recombinant Gal1 (rGal1). The addition
of rGal1 increased in vitro proliferation, migration, and invasion of
RWP-1 cells (Fig. S5) similarly to our findings using HPSC con-
ditioned medium. Gene-expression profiling using the GeneChip
Human Gene 2.0 ST expression array revealed 339 genes differ-
entially expressed between RWP-1 cells grown in basal condi-
tions and cells treated with rGal1, of which 156 genes were up-
regulated, and 183 genes were down-regulated (Fig. 6A and
Dataset S1).
Gene ontology (GO) analysis of Gal1 target genes identified
a significant enrichment in genes involved in tumor biology,
including cell signaling, motility, morphology, inflammatory responses,
immune cell trafficking, cell commitment, tumor morphology,
Fig. 3. Characterization of pancreatic tumors from 4-mo-old Ela-KrasG12Vp53−/−Lgals1+/+ and Ela-KrasG12Vp53−/−Lgals1−/− mice. (A) Representative images
(Upper) and box-and-whisker plots (Lower) showing the weights of pancreatic tumors from Ela-KrasG12Vp53−/−Lgals1+/+ and Ela-KrasG12Vp53−/−Lgals1−/− mice.
(Scale bars: 1 cm.) (B, Left) Histochemical analysis of activated stroma (α-SMA staining) and vascularization [von Willebrand factor (vWF) staining] of pancreatic
tumors from Ela-KrasG12Vp53−/−Lgals1+/+ and Ela-KrasG12Vp53−/−Lgals1−/− mice. (Scale bars: 100 μm for α-SMA and 50 μm for vWF.) (Right) Quantifications
expressed as the percentage of α-SMA–stained area per field or the percentage of vWF staining relative to the number of tumor cells. *P < 0.05. (C) Flow
cytometry analysis of immune cell infiltrates associated with pancreatic tumors from Ela-KrasG12Vp53−/−Lgals1+/+ or Ela-KrasG12Vp53−/−Lgals1−/− mice. Rep-
resentative plots of tumor-infiltrating immune cells expressing CD45, CD3, CD4, and CD8 or CD11b and Gr-1 are shown. Percentages of cells of each individual
subpopulation (CD3+CD4+ cells, CD3+CD8+ cells, and CD11b+Gr-1+ cells) are indicated. **P < 0.01, ***P < 0.001 (Student’s t test). Ten animals per group were
used for the characterizations in A–C.
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and signaling pathways (Fig. 6B). Of note, Ingenuity Pathway
Analysis showed associated network functions related to cellular
motility, growth, and proliferation (Fig. 6C), which correlated
well with the biological functions displayed by Gal1 in experi-
mental mouse and human PDA models. Top disease analyses
identified the most significant enrichment in cancer-related
molecules, and biofunction classification distinguished the cell
cycle, motility, morphology, assembly, and cell commitment
pathways (Table S2).
To gain further insight into the molecular pathways driven by
Gal1 in human pancreatic cancer, we selected several cancer-
related candidates from the list of genes differentially expressed in
RWP-1 cells after rGal1 treatment and validated their expression
levels by RT-qPCR (Fig. 6D). Interestingly, exposure of RWP-
1 cells to rGal1 resulted in a significant overexpression of genes
involved in cell proliferation and metastasis (IL1A and MMP1),
migration (S100A7 and ANK3), cell metabolism (EXTL2 and
GPCPD1), and other pathways (ASXL3, AGPAT9, GALNT16,
and TOX), as well as down-regulation of the Hedgehog (Hh) in-
hibitor DHCR7, the putative tumor-suppressor gene INSIG1 (50),
and other genes with uncertain roles in cancer (TFRC, CLCNK8,
and ROCK1).
These findings identify gene networks that are directly or in-
directly modulated by Gal1 in pancreatic epithelial tumor cells,
thus providing a molecular perspective on the mechanisms in-
volved in tumor–stroma crosstalk and their impact in pancreatic
cancer progression.
Discussion
Improving pancreatic cancer patients’ outcome is an important
unmet clinical need. Alarmingly, both its incidence and associ-
ated death rates are increasing, so that pancreatic cancer is now
in the third position of the top cancer killers in the United States
and is anticipated to become the second leading cause of cancer
death by 2030 (51). To improve the currently bleak perspectives
for most PDA patients, it is critical to identify new molecular
targets for the development of effective treatments. Here, using
a combination of GEMM- and human-based experimental sys-
tems, we provide evidence that inhibition of Gal1, a protein
overexpressed by stromal fibroblasts, may hinder PDA tumor
progression by impeding an efficient tumor–stroma crosstalk,
thereby supporting the use of Gal1 inhibitors as a pharmaco-
logical weapon for the treatment of pancreatic cancer patients,
either alone or in combination with immunotherapeutic, che-
motherapeutic, or targeted strategies.
PDA is unique in its stromal composition, which frequently
accounts for more than 90% of the tumor mass. In fact, this
dense fibrotic barrier is considered one of the major reasons for
PDA resistance to therapies (3, 52). Another key hallmark of
PDA is KRAS mutations, which are present in >90% of PDA
patients (24) and are essential for tumor initiation and pro-
gression (53, 54). Importantly, mouse Kras-driven models re-
capitulate not only these two features of human PDA but also its
profound immunosuppression (33) and tumor genetic hetero-
geneity (55–60). These hallmarks strongly support the use of
these mice for preclinical validation of novel targeted therapies.
We previously reported a beneficial effect of Gal1 inhibition
using a c-myc–driven PDA model (43); however, these mice did
not fully recapitulate the tumor progression found in human
disease (61). In contrast, the Ela-KrasG12Vp53−/− mice used in
this work faithfully recapitulate the full spectrum of pancreatic
intraepithelial neoplasias that progress to human-like PDA tu-
mors and, like PDA patients, develop liver metastases (28, 48),
thus making this model an ideal system for testing novel mo-
lecular targets. Using this Kras-driven model, we have found that
genetic ablation of Gal1 increases animal survival and constrains
tumor growth through multiple mechanisms involving decreased
stroma activation and angiogenesis as well as augmented im-
mune cell infiltration. Moreover, we demonstrated that Gal1 is
involved not only in pancreatic tumor initiation but also at late
stages of tumor progression, as shown by the reduction in liver
metastases after Gal1 genetic deletion (Fig. 7). Remarkably, we
also confirmed the induction of tumor progression and metas-
tasis by stromal Gal1 using a human cell-based system that fully
recapitulates Gal1-mediated tumor–stroma crosstalk in human
PDA (Fig. 7), unveiling the potential translation of these results
to PDA clinical setting.
Collectively, our studies in mouse and human settings indicate
that pancreatic cancer stromal Gal1 exerts both autocrine and
paracrine protumoral functions. First, Gal1 secreted by PSCs in-
duces stroma activation through an autocrine loop. In this regard,
previous data using different in vitro and in vivo models have
shown Gal1-mediated activation of PSC by triggering the ERK or
Hh signaling pathways (43, 62, 63), although further studies are
required to elucidate whether these mechanisms are also re-
sponsible for Gal1 induction of stroma activation in the Kras-driven
model. On the other hand, Gal1 orchestrates a paracrine crosstalk
with epithelial cells to induce proliferation, migration, and invasion,
as well as with endothelial and inflammatory cells to promote an-
giogenesis and immune cell inhibition. Of note, the induction of
cell proliferation in tumor epithelial cells by Gal1 is observed only
in the in vitro setting, suggesting that non–cell-autonomous
mechanisms or differences in kinetics during the in vivo experi-
ments may account for this discrepancy. Different molecular
Fig. 4. Crosstalk between HPSCs and pancreatic tu-
mor cells is mediated by HPSC-secreted Gal1. (A, Left)
Western blot analysis of Gal1 protein expression levels
in supernatants of control HPSCs (Ctl), cells infected
with shSC, or cells infected with two different Gal1-
specific sequences (shGal1_1 and shGal1_2). (Right)
Quantification. (B) ELISA quantification of Gal1 levels
in supernatants of HPSC control cells (Ctl) or shSC-,
shGal1_1-, or shGal1_2-infected cells. (C) Effects of
conditioned medium (CM) from Gal1-depleted HPSCs
on RWP-1 cell proliferation using immunofluores-
cence against the P-HisH3 marker. (D) Effects of
conditioned medium from Gal1-depleted HPSCs on
RWP-1 migration using a Transwell assay. (E) Ef-
fects of conditioned medium from Gal1-depleted
HPSCs on the invasion of RWP-1 cells through
Matrigel-coated Transwells. Data are given as the
mean ± SEM of three independent experiments.
*P < 0.05 and **P < 0.01 relative to shSC.

















Fig. 5. Depletion of Gal1 in HPSCs reduces tumor size, angiogenesis, stroma activation, and metastasis after orthotopic coinjection with BxPC-3 pancreatic
tumor cells. (A, Upper) A representative tumor for each group is shown. (Scale bars: 1 cm.) (Lower) Box-and-whisker plot representation of the tumor weight
of orthotopic xenograft mice injected with BxPC-3 cells alone or with control HPSCs (shSC) or Gal1-knocked down (shGal1_1 and shGal1_2) HPSCs. *P < 0.05,
relative to shSC. (B) Representative photographs of H&E-stained tumors in each group. Tumors display undifferentiated features and frequent necrotic areas.
(Scale bars: 200 μm.) (C, Upper) Analysis of cell proliferation (P-HisH3 staining), vascularization (vWF staining), and activated stroma (α-SMA staining) in
orthotopic xenografts tumors frommice injected with BxPC-3 cells alone or with HPSCs infected with shSC, shGal1_1, or shGal1_2. (Scale bars: 100 μm.) (Lower)
Quantifications are expressed as the percentage of cells with P-HisH3+ staining, the percentage of vWF staining relative to the number of tumor cells, and the
percentage of α-SMA+ area per field. ***P < 0.001, relative to shSC. (D, Left) Representative images of pancreatic metastases using CK19 IHC staining (liver) or
H&E staining (lung). (Scale bars: 50 μm.) (Right) Quantification of the percentage of mice with liver and lung metastases (P = 0.20, χ2 test).
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mechanisms might be responsible for Gal1 paracrine functions.
Microarray gene-expression analysis of human pancreatic tumor
cells exposed to exogenous Gal1 revealed the prominent rele-
vance of gene networks related to cell cycle, cellular migration,
and tumor morphology among the top Gal1-regulated pathways,
which might explain the effects of PSCs on epithelial tumor cells.
In particular, we have validated the up-regulation of several target
genes with previously established roles in PDA cell growth and
invasion, such as IL1A and MMP1 (64–66), as well as other genes
involved in cell migration (i.e., S100A7 and ANK3) (67, 68) and in
cell growth and metastasis in other tumors (TOX) (69). In-
terestingly, we also found down-regulation of DHCR7, a negative
regulator of the Hh signaling pathway (70), which is in agreement
with our previous results showing that Gal1 mediates the activa-
tion of the Hh pathway in PDA cells, thereby promoting endo-
thelial cell proliferation and migration (43). In this regard, a direct
role of Gal1 in tumor angiogenesis has been well established (71–
75), implicating this lectin as a critical mediator of hypoxia-driven
and VEGF-independent angiogenesis (76). Interestingly, PDA
displays a highly hypoxic microenvironment (77, 78) that could
favor Gal1 overexpression (75, 76, 79). In addition, our microarray
data suggest that Gal1 can also promote angiogenesis in PDA
through an indirect mechanism mediated by the up-regulation of
IL-1α, which might induce secretion of proangiogenic cytokines
(80), or by the down-regulation of the transferrin receptor
(TFRC), which may promote hypoxia and augment tumor an-
giogenesis (81). Moreover, aberrant N-glycosylation has been re-
cently reported in human PDA cell lines compared with normal
pancreatic cells (82), suggesting that glycan remodeling might
promote the exposure of Gal1 ligands and regulate its biological
function during tumor progression.
Interestingly, Gal1 deletion in the Ela-KrasG12Vp53−/− mice fa-
cilitated immune cell infiltration, indicating that this lectin has a
Fig. 6. Molecular pathways triggered by Gal1 in human pancreatic cancer.
(A) Heatmap diagram of differential gene expression (with P < 0.01) in RWP-
1 cells treated with rGal1 compared with untreated cells. (B) GO analysis of
genes differentially expressed in RWP-1 cells after rGal1 treatment. The bar plot
shows the log10 P value of the biological process GO terms obtained with dif-
ferentially expressed genes with P < 0.01. (C) Ingenuity Pathway Analysis
showing the top network functions of the genes regulated by rGal1 in RWP-
1 cells. (D) RT-qPCR validation of gene-expression changes triggered by
rGal1 treatment of pancreatic tumoral cells. Up-regulated or down-regulated
genes found in the microarray analysis were validated by measuring the relative
mRNA fold change by RT-qPCR in rGal1-treated cells (black bars) compared with
untreated cells (control; gray bars). RNA levels were normalized using GAPDH as
a housekeeping gene. Data are given as the mean ± SEM of three independent
experiments. *P < 0.05; **P < 0.005; ***P < 0.0005 (Student’s t test).
Fig. 7. Effects of Gal1 targeting in the control of pancreatic tumor pro-
gression. The role of Gal1 in pancreatic tumor progression was addressed in
two experimental model systems: by genetically depleting Gal1 in the PDA
model Ela-KrasG12Vp53−/− (Left) and by analyzing tumor–stroma crosstalk in a
human-based in vitro system in which HPSCs with normal or down-regulated
Gal1 levels (KD Gal1) were used for in vitro (CM) or in vivo (nude mice xe-
nograft coinjection) strategies. Microarray analysis of pancreatic epithelial
cells treated with rGal1 was also performed to depict the molecular scenario
responsible for Gal1 effects on the epithelium. These data are summarized in
the model, showing that Gal1 inhibition results in impaired migration, in-
vasion, stroma activation, cell proliferation, angiogenesis, and metastasis
while increasing tumor-immune infiltrates, ultimately leading to reduced tumor
progression. Images adapted with permission from smart.servier.com.

















critical role in impairing immune surveillance during PDA pro-
gression. In this sense, PDA is accompanied by a profound
immunosuppressive microenvironment characterized by the
accumulation of immature MDSCs and a conspicuous absence of
tumor-infiltrating T lymphocytes, a scenario that is fully mim-
icked in the Kras-driven mouse models (33). This inhibitory mi-
lieu might explain why PDA patients do not respond to immune
checkpoint-blockade therapies (23). Notwithstanding, recent
genome-wide studies have identified molecular signatures (83)
and unique neoantigen properties (84) that may be useful for
stratifying PDA patients for immunotherapy. Data from murine
PDA models have provided new mechanisms for PDA immuno-
suppression, showing that MDSCs can be recruited through Kras-
driven paracrine secretion of GM-CSF by tumor cells (85, 86).
Here, we demonstrate that Gal1 also plays a key role in MDSCs
accumulation in Kras-driven PDA, as this regulatory cell pop-
ulation was dramatically reduced in Ela-Kras Gal1-KO mice. Ac-
cordingly, previous studies showed that Gal1 can promote the
differentiation and selective retention of tolerogenic dendritic
cells in inflamed tissues (87, 88) and may favor recruitment of
MDSCs in a glioblastoma model (89). In parallel, we found that
deletion of the Gal1 gene induces up-regulation of CD4+ and
CD8+ T cell tumor infiltrates as shown in other tumor types, in-
cluding melanoma (90), Hodgkin lymphoma (91), neuroblastoma
(92), lung adenocarcinoma (93), ovary carcinoma (94), and breast
adenocarcinoma (95). This effect may be directly related to T cell
dysfunction induced by Gal1, as this lectin impairs T cell viability
and suppresses the synthesis of T cell-derived proinflammatory
cytokines (45, 96), or may involve the repression of regulatory
circuits mediated by MDSCs or tolerogenic dendritic cells, leading
to subsequent expansion of effector T cells (97). Interestingly,
although Lgals1−/− mice did not originally show any overt pheno-
typic abnormality (98), more recent studies demonstrated that
these animals develop more exacerbated immune responses when
challenged by inflammatory or infectious stimuli (87, 96, 99, 100),
suggesting that this lectin could be specifically targeted to augment
T cell infiltration and reinvigorate antitumor immunity.
The pleiotropic functions exerted by Gal1 during PDA tumor
progression suggest its potential role as an ideal therapeutic
target. Gal1 inhibitors would simultaneously block the tumor and
the stroma compartment, inhibiting tumor cell proliferation,
vascularization, and fibroblast activation, while restoring im-
mune surveillance. Thus, pharmacological inhibition of Gal1 or
its glycosylated ligands using specific monoclonal antibodies,
glycan inhibitors, or peptidomimetics could have a strong impact
on PDA progression and contribute to enhancing the efficacy of
currently available immunotherapeutic modalities. Interestingly
Gal1-neutralizing antibodies have shown promising results in
xenografts of Kaposi’s sarcoma and syngeneic models of mela-
noma and lung cancer (75, 76).
In conclusion, our study validates Gal1 as a multifunctional
target during PDA progression and paves the way toward the
development of a new generation of drugs targeting the unique
PDA microenvironment.
Materials and Methods
Animal Breeding and Use and Sample Collection. K-Ras+/LSLG12V;Elas-tTA/tetO-
Cre;p53lox/lox mice were obtained from C. Guerra and M. Barbacid, Centro
Nacional de Investigaciones Oncológicas (CNIO), Madrid (28, 48) and were
crossed with Gal- KO (Lgals1−/−) mice for Gal1 depletion in this model. Ela-
KrasG12Vp53−/−Lgals1+/+ (n = 18) and Ela-KrasG12Vp53−/−Lgals1−/− (n = 17)
mice were killed at 4 mo of age for detailed histopathological character-
ization. For endpoint survival analysis, Ela-KrasG12Vp53−/−Lgals1+/+ (n = 20)
and Ela-KrasG12Vp53−/−Lgals1−/− (n = 19) mice were killed according to ap-
proved ethical guidelines when animal welfare was compromised. Pancreatic
tumors, liver, and lungs were resected, weighed, fixed in 10% formaldehyde,
and embedded in paraffin. All procedures were approved by the Barcelona
Biomedical Research Park (PRBB) Ethical Committee for Animal Experimentation.
Histopathological Assessment. To screen for pancreatic precursor lesions or
metastasis formation, paraffin-embedded full pancreata (precursor lesions)
or livers and lungs (metastasis) were completely sliced. H&E staining was
performed every 30 μm to screen for pancreatic lesions or foci of metastasis,
which were all confirmed by an expert pathologist. Histological tissue pa-
rameters such as tumor architecture, desmoplasia, node infiltration, necrosis,
apoptosis, and immune infiltration were analyzed under the supervision of
an expert pathologist.
Immunohistochemistry and Immunofluorescence. Paraffin-embedded samples
were cut at 3 μm for immunohistochemistry (IHC) analysis, as previously
described (101), using the antibodies listed in SI Materials and Methods.
Quantification was done by taking 10 images per tumor using an Olympux
BX61 motorized microscope. Images were processed using ImageJ software
(NIH) in which positively and negatively stained areas or cells were mea-
sured. Results are expressed as the percentage of positive area in each high-
power field or the percentage of positive cells per field, where indicated.
Immunofluorescence was performed as described (101) using the antibodies
listed in Supporting Information and a Leica DM6000 digital microscope.
Flow Cytometry of Tumor-Associated Immune Infiltrates. Ten 4-mo-old mice
per genotype were killed, and a piece of the resected pancreatic tumor was
clipped and processed as previously described (33). Antibodies for blocking and
surface labeling are listed in Supporting Information. For staining controls,
unstained, fluorescenceminus one (FMO), and individual stained controls were
included for all surface-marker combinations. Cells were stained with DAPI
(Sigma) and analyzed by FACS in a LSRII flow cytometer (BD Bioscience) at the
Pompeu Fabra University (UPF) Flow Cytometry facility.
Cell Lines. HPSC were generated as previously described (14). HEK293T cells
(102) and the human pancreatic ductal tumor cell lines RWP-1 (103) and
BxPC-3 (104) were obtained from the cancer cell repository at Hospital del
Mar Medical Research Institute (IMIM), Barcelona. Cells were cultured at
37 °C in a cell incubator at 5% CO2 using DMEM (Gibco) with 10% FBS.
Gal1 Down-Regulation in HPSCs. shRNA-mediated Gal1 down-regulation was
achieved with lentiviral particles generated in HEK-293T cells encoding the
pLKO-1 vector, Mission RNAi, shGal1, TRCN0000057424,427 (Sigma), or
control shSC (SHC002).
Protein Lysates and Western Blot Analysis. Total protein extracts were
obtained by lysing cells in 1× Laemmli buffer (60 mM Tris-Cl pH 6.8, 2% SDS,
10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue). Protein
expression was detected by SDS/PAGE under reducing conditions, and im-
munoblotting was performed with anti-Gal1 (Abcam), anti-fibronectin
(Sigma), anti-GFAP (Sigma), anti–α-SMA (Sigma), anti-GAPDH (Abcam), and
anti-tubulin (Sigma) antibodies. HRP-conjugated secondary antibodies
(Dako) followed by ECL (Thermo Fisher) incubation allowed protein
band detection.
Preparation of HPSC-Conditioned Medium. HPSCs were cultured in 75-cm2
flasks with DMEM and 10% FBS. Upon 80% confluence, cells were left with
4 mL of serum-free DMEM, and secreted factors were collected after 48 h.
Gal1 protein was quantified by ELISA (R&D Systems).
Cell Proliferation Assay. For HPSCs proliferation assays, 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide] (MTT) staining was performed as
described (101). For tumor–stroma crosstalk and proliferation assays using
rGal1 (105), cells were starved for 48 h and stimulated with conditioned me-
dium from HPSCs or rGal1 for 24 h. Cell proliferation was measured by
phospho-histone H3 (P-HisH3) staining (see Immunofluorescence above).
Twenty photographs at 20× magnification were taken, and proliferation was
measured using ImageJ software quantifying the ratio between P-HisH3+ cells
and the total number of cells (DAPI).
Migration Assays. To evaluate migration in HPSCs, wound healing was per-
formed as described (42). For tumor–stroma crosstalk experiments, epithelial
cells were seeded in 96-well Transwells (8 μm; Corning). Conditioned me-
dium from HPSCs or DMEM as a negative control was added to the lower
chamber, and migration was assessed after 72 h by quantifying cells through
hexosaminidase enzymatic substrate uptake and absorbance at 410 nm in a
spectrophotometer (200 series; Tecan). For experiments using rGal1, a cell
radius migration assay kit (Cell Biolabs) was used following the manufac-
turer’s instructions. Images of the gap closure were taken with a bright-light
microscope, and the covered area was quantified using ImageJ software.
E3776 | www.pnas.org/cgi/doi/10.1073/pnas.1722434115 Orozco et al.
Invasion Assays. Cells were seeded in Matrigel-coated 96-well Transwells
(8 μm; Corning). DMEM with 10% FBS, conditioned medium from HPSCs (for
tumor–stroma crosstalk assays), rGal1, or DMEM as a negative control was
added to the lower chamber. Cells that invaded to the bottom layer were
quantified by hexosaminidase enzymatic substrate uptake after 72 h.
Orthotopic Coinjection in BALB/C Nude Mice. Pancreatic orthotopic injection
was performed following the guidelines described by Kim et al. (106), using
7-wk-old BALB/c nude mice (Charles River; five mice per group). BxPC-3 cells
and HPSCs were injected at a 1:5 ratio (4 × 105 and 2 × 106 cells, respectively).
Tumors were monitored once a week for 5 wk; then all animals were killed.
Reverse Transcription and Real-Time qPCR Analysis. RNAwas isolated using the
total RNA extraction kit (Sigma) or the RNeasy Plus Mini kit (Qiagen) for
microarray analysis. RNA was analyzed in a NanoDrop ND-1000 spectropho-
tometer (NanoDrop Technologies) and a Bioanalyzer 2100 (Agilent Technol-
ogies). RNA was retro-transcribed (RevertAid First Strand cDNA Synthesis Kit;
Thermo Scientific). Human HPRT and GAPDH were used as housekeeping
genes. qRT-PCR (n = 3) was performed by SYBR Green on the QuantStudio
Real-Time PCR System (Life Technologies) using the primers listed in Table S3.
Microarray Analysis and Bioinformatics. Microarray samples were processed
according to the protocol described in the GeneChip WT PLUS Reagent Kit
and then hybridized to GeneChip Human Gene 2.0 ST Array (Affymetrix) in a
GeneChip Hybridization Oven 640. Details and computational analysis are
described in Supporting Information. Data have been deposited in the Na-
tional Center for Biotechnology Information Gene Expression Omnibus
(GEO) with the GEO Series accession number GSE109070.
Statistical Analysis.Data analyses were carried out using SPSS statistics version
20 software (IBM). P < 0.05 was considered statistically significant (*P < 0.05;
**P < 0.01; ***P < 0.001). Unless otherwise stated, all data are expressed as
the relative mean of three independent experiments, and error bars indicate
the SEM. Comparisons were made through Student’s t test for normally
distributed data; χ2 was used to analyze metastasis data. Kaplan–Meier
survival analysis and a log-rank test were used to plot mouse survival.
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